Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.78Last Year’s EPS
-0.63Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -3.77%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The call conveyed optimism around the resubmission and approval prospects of narsoplimab, as well as the progress in Zaltenibart's development. However, financial challenges persist, as evidenced by ongoing net losses and decreased OMIDRIA royalties.Company Guidance
During the earnings call, Omeros Corporation provided guidance on its financial performance and strategic initiatives for 2024. The company reported a net loss of $31.4 million, or $0.54 per share, for the fourth quarter, and a full-year net loss of $156.8 million, or $2.70 per share. As of December 31, 2024, Omeros had over $90 million in cash and investments. The company is in discussions to restructure its 2026 convertible notes and explore potential partnerships to bolster its financial position. Omeros has resubmitted its Biologics License Application (BLA) for narsoplimab in TA-TMA, with a PDUFA date set for September. Additionally, the company is advancing its Zaltenibart program, now in Phase 3 development for paroxysmal nocturnal hemoglobinuria (PNH), aiming for data submission by the fourth quarter of next year. Omeros is also preparing for the commercial launch of narsoplimab, with significant interest from transplant centers and ongoing efforts to secure ICD10 and CPT codes for reimbursement.Progress in Narsoplimab Approval
Omeros resubmitted the BLA for narsoplimab for TA-TMA treatment, showcasing significant survival benefits with a more than three-fold improvement in survival. The resubmission included strong statistical support and has a PDUFA date set for September 2025.
Zaltenibart Development
Zaltenibart is in Phase 3 development for PNH, with promising results in preliminary trials showing strong efficacy. The compound is expected to be a preferred choice for alternative pathway-related diseases due to its enhanced efficacy and convenient dosing.
Strong Cash Position
As of December 31, 2024, Omeros had over $90 million in cash and investments, indicating a solid financial position to support ongoing operations and developments.
Ongoing Development Pipeline
Continued advancement in multiple therapeutic areas, including the development of OMS1029 and OMS527, and promising progress in oncology and infectious disease programs.
---
OMER Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OMER Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $8.22 | $7.91 | -3.77% |
| Nov 13, 2024 | $4.19 | $6.95 | +65.87% |
| Aug 07, 2024 | $4.15 | $3.91 | -5.78% |
| May 15, 2024 | $4.17 | $3.31 | -20.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Omeros Corp (OMER) report earnings?
Omeros Corp (OMER) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Omeros Corp (OMER) earnings time?
Omeros Corp (OMER) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OMER EPS forecast?
OMER EPS forecast for the fiscal quarter 2025 (Q1) is -0.78.
---